European CHMP recommends approval of encorafenib for the treatment of metastatic colorectal cancer (CRC)

The CHMP has issued a positive opinion, recommending approval of encorafenib for this additional indication; specifically for use in combination with cetuximab, for the treatment of adults with metastatic CRC with a BRAF V600E mutation, who have received prior systemic therapy.


European Medicines Agency